Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Loxo Oncology Inc.
Sponsor

Loxo Oncology Inc.

United States 281 Tresser Boulevard Floor 9th, 06901-3238, United States

About the sponsor

Clinical research in CLL/SLL centers on pirtobrutinib and related Bruton’s tyrosine kinase-targeted approaches for patients with previously treated disease, untreated disease, and BTK-inhibitor exposure.

  • Progression-free survival
  • Overall response rate
  • Combination therapy with venetoclax and rituximab

Studies also include comparisons with bendamustine plus rituximab and idelalisib-based regimens in relapsed or refractory settings.

About Specializations

Loxo Oncology Inc. runs clinical trials in conditions such as Chronic lymphocytic leukaemia, Medullary thyroid cancer, Neoplasm, Non-small cell lung cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

8 clinical trials

Chronic lymphocytic leukaemia

Recruiting

Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Neoplasm+2

Not recruiting

Study on the Effects of Selpercatinib in Patients Aged 12 and Older with Advanced Solid Tumors with RET Gene Alteration

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Loxo Oncology Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Chronic lymphocytic leukaemia+2

Not recruiting

Study of Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Neoplasm malignant+2

Not recruiting

Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Selpercatinib
  • Sponsor:Loxo Oncology Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.